Chain Drug Review - FDA approves applications for two drugs made by GSK
GlaxoSmithKline PLC has received two significant marketing approvals from the Food and Drug Administration. Requip has been cleared as a treatment for moderate-to-severe restless legs syndrome in adults. Boostrix has been given the O.K. as the first combination vaccine to help protect adolescents against whooping cough.
Related Results
Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome.
COPYRIGHT 2005 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
